172 related articles for article (PubMed ID: 22014454)
1. Clozapine protects bone mineral density in female patients with schizophrenia.
Lin CH; Huang KH; Chang YC; Huang YC; Hsu WC; Lin CY; Huang-Chih Chou F; Tsai GE; Lane HY
Int J Neuropsychopharmacol; 2012 Aug; 15(7):897-906. PubMed ID: 22014454
[TBL] [Abstract][Full Text] [Related]
2. The use of clozapine is protective for low bone mineral density induced by prolactin-raising antipsychotics in inpatients with schizophrenia.
Qiu J; Gong H; Wang B; Gu W; Wang L; Gu M; Zhang Y; Du X
Arch Osteoporos; 2020 Jun; 15(1):98. PubMed ID: 32601884
[TBL] [Abstract][Full Text] [Related]
3. Long-term Use of Clozapine is Protective for Bone Density in Patients with Schizophrenia.
Lin CH; Lin CY; Wang HS; Lane HY
Sci Rep; 2019 Mar; 9(1):3895. PubMed ID: 30846868
[TBL] [Abstract][Full Text] [Related]
4. The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia: findings from a longitudinal observational cohort.
Takahashi T; Uchida H; John M; Hirano J; Watanabe K; Mimura M; Correll CU; Kishimoto T
Schizophr Res; 2013 Jul; 147(2-3):383-6. PubMed ID: 23668975
[TBL] [Abstract][Full Text] [Related]
5. Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables.
Meaney AM; O'Keane V
Schizophr Res; 2007 Jul; 93(1-3):136-43. PubMed ID: 17467954
[TBL] [Abstract][Full Text] [Related]
6. Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study.
Wang M; Hou R; Jian J; Mi G; Qiu H; Cao B; Tang M
Hum Psychopharmacol; 2014 Mar; 29(2):183-9. PubMed ID: 24738111
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Antipsychotics on Bone Mineral Density and Sex Hormones in Male Patients with Schizophrenia.
Bulut SD; Bulut S; Atalan DG; Tulaci RG; Türker T; Gürçay E; Aydemir Ç
Psychiatr Danub; 2016 Sep; 28(3):255-262. PubMed ID: 27658834
[TBL] [Abstract][Full Text] [Related]
8. Sex-specific factors for bone density in patients with schizophrenia.
Lin CH; Lin CY; Huang TL; Wang HS; Chang YC; Lane HY
Int Clin Psychopharmacol; 2015 Mar; 30(2):96-102. PubMed ID: 25521694
[TBL] [Abstract][Full Text] [Related]
9. Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone.
Doknic M; Maric NP; Britvic D; Pekic S; Damjanovic A; Miljic D; Stojanovic M; Radojicic Z; Jasovic Gasic M; Popovic V
Neuroendocrinology; 2011; 94(3):246-54. PubMed ID: 21986470
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?
O'Keane V; Meaney AM
J Clin Psychopharmacol; 2005 Feb; 25(1):26-31. PubMed ID: 15643097
[TBL] [Abstract][Full Text] [Related]
11. Effects of Antipsychotics on Bone Mineral Density in Patients with Schizophrenia: Gender Differences.
Chen CY; Lane HY; Lin CH
Clin Psychopharmacol Neurosci; 2016 Aug; 14(3):238-49. PubMed ID: 27489377
[TBL] [Abstract][Full Text] [Related]
12. Gender-specific risk factors for low bone mineral density in patients taking antipsychotics for psychosis.
Jhon M; Yoo T; Lee JY; Kim SY; Kim JM; Shin IS; Williams L; Berk M; Yoon JS; Kim SW
Hum Psychopharmacol; 2018 Jan; 33(1):. PubMed ID: 29315805
[TBL] [Abstract][Full Text] [Related]
13. Bone mineral density and prolactin associations in patients with chronic schizophrenia.
Howes O
Schizophr Res; 2004 Jan; 66(1):77-8. PubMed ID: 14693356
[No Abstract] [Full Text] [Related]
14. Osteoporosis in patients with schizophrenia.
Hummer M; Malik P; Gasser RW; Hofer A; Kemmler G; Moncayo Naveda RC; Rettenbacher MA; Fleischhacker WW
Am J Psychiatry; 2005 Jan; 162(1):162-7. PubMed ID: 15625215
[TBL] [Abstract][Full Text] [Related]
15. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia.
Meaney AM; Smith S; Howes OD; O'Brien M; Murray RM; O'Keane V
Br J Psychiatry; 2004 Jun; 184():503-8. PubMed ID: 15172944
[TBL] [Abstract][Full Text] [Related]
16. Bone Mineral Density in Schizophrenia: An Update of Current Meta-Analysis and Literature Review Under Guideline of PRISMA.
Tseng PT; Chen YW; Yeh PY; Tu KY; Cheng YS; Wu CK
Medicine (Baltimore); 2015 Nov; 94(47):e1967. PubMed ID: 26632691
[TBL] [Abstract][Full Text] [Related]
17. Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study.
Üçok A; Çıkrıkçılı U; Ergül C; Tabak Ö; Salaj A; Karabulut S; Correll CU
CNS Drugs; 2016 Oct; 30(10):997-1006. PubMed ID: 27356920
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of desacyl ghrelin in patients with schizophrenia on clozapine monotherapy.
Wysokiński A; Kowalski ML; Kłoszewska I
Psychiatry Clin Neurosci; 2014 Dec; 68(12):833-840. PubMed ID: 24773632
[TBL] [Abstract][Full Text] [Related]
19. Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study.
Bai YM; Chen TT; Yang WS; Chi YC; Lin CC; Liou YJ; Wang YC; Su TP; Chou P; Chen JY
Schizophr Res; 2009 Jun; 111(1-3):1-8. PubMed ID: 19409756
[TBL] [Abstract][Full Text] [Related]
20. Switching from clozapine to zotepine in patients with schizophrenia: a 12-week prospective, randomized, rater blind, and parallel study.
Lin CC; Chiu HJ; Chen JY; Liou YJ; Wang YC; Chen TT; Bai YM
J Clin Psychopharmacol; 2013 Apr; 33(2):211-4. PubMed ID: 23422395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
